Enlivex Ltd.
ENLVHealthcareNASDAQBiotechnology · Last scanned Sep 5, 2026
Scan Results
Daily timeframePart of the healthcare sector, Enlivex Ltd. (ENLV) is listed under Biotechnology. Valued at $19.2M, ENLV is a micro-cap name in its sector. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2.
Market Cap
$19.2M
Beta
1.42
P/E (TTM)
0.00
P/E (Fwd)
-1.41
EPS (TTM)
$362.43
EPS (Fwd)
$-0.78
ROE
126.2%
ROA
-0.8%
Cash
$5.8M
Total Debt
$641,000
Free CF
-$1.74B
52W Change
-92.6%
Annual Financials
Cash vs Debt
Where ENLV stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ENLV finished 88.13% below its 150-day moving average ($10.53) and 89.03% below its 200-day moving average ($11.39). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ENLV overbought or oversold?
At the September 3, 2026 close, ENLV's RSI(14) was 27.1, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $5.8M in cash comfortably exceeding the $641K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$1.74B, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at 126.2%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, ENLV has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing ENLV's risk profile alongside its fundamentals and technical indicators provides a more complete picture.